Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
325 Leser
Artikel bewerten:
(2)

Avania Strengthens Leadership Team with Appointment of Four New Executives

BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025, the leading global MedTech advisory and clinical development partner, is pleased to announce strategic leadership appointments of four distinguished executives. As the MedTech industry navigates increasing regulatory complexity and technological innovation, these new leaders bring decades of combined experience in clinical research, regulatory affairs, operations, information technology, and business development, further reinforcing Avania's commitment to excellence and growth.

The newly appointed executives are:

  • Angela Johnson (https://www.avaniaclinical.com/leadership-team/angela-johnson/), PhD, RAC,Senior Vice President, Advisory Services - Dr. Johnson has more than 25 years of experience leading regulatory strategy (https://www.avaniaclinical.com/solutions/emerging-technology-and-product-development-strategy/), clinical development, and market access (https://www.avaniaclinical.com/solutions/market-access/) initiatives for medical devices, combination products, and AI/SaMD technologies, ranging from early-stage ventures to multinational companies. As leader of Avania's global advisory practice, she partners with MedTech innovators to navigate FDA, EU (MDR/IVDR), Asia-Pacific (TGA, PMDA, NMPA), and global regulatory frameworks. Her expertise strengthens Avania's ability to deliver high-impact, insight-driven counsel, accelerating time-to-market for breakthrough technologies, and enabling clients to thrive in an increasingly complex, evolving global landscape.
  • Paul Southam (https://www.avaniaclinical.com/leadership-team/paul-southam/), Chief Information Officer (CIO) - Southam joins Avania as Chief Information Officer, bringing over two decades of global leadership experience in information technology and digital transformation. With a proven track record of aligning IT strategy with business objectives, Paul will lead Avania's global technology initiatives - driving innovation, security, and operational efficiency across the organization.
  • Marianne Martin, Vice President, Global Project Management - Martin has over 20 years of global leadership experience in clinical research operations (https://www.avaniaclinical.com/solutions/clinical-operations/) and program delivery, spanning multiple therapeutic areas and including medical devices and combination products. Martin has a strong track record of successfully leading complex, global, multi-center clinical trials, with deep expertise in the fundamentals of project management and customer service. Martin will oversee Avania's global project management teams, ensuring operational excellence and strategic alignment across all client programs.
  • Karen Auten, Vice President, Global Clinical Operations (https://www.avaniaclinical.com/solutions/clinical-operations/) - Auten brings over two decades of leadership in clinical research, global clinical trial management, program delivery, and operational strategy within the medical device and life sciences industries. Auten will lead Avania's global clinical operations, overseeing the execution of clinical trials from first-in-human through post-market studies. Auten is recognized for her ability to lead high-performing teams, streamline operational processes, and deliver impactful results in complex, regulated environments. Auten's appointment underscores Avania's commitment to advancing clinical innovation and operational excellence on a global scale.

"These appointments mark an exciting chapter in Avania's evolution as we scale to meet increasing global demand for MedTech regulatory and clinical expertise," said Jason Monteleone, Chief Executive Officer of Avania. "Each of these leaders brings a unique set of skills and insights that align with our mission to advance MedTech innovation through expert-driven, customized solutions. Their collective expertise will help us better serve our clients, and navigate the dynamic healthcare landscape."

With these appointments, Avania strengthens its position as the premier global partner for MedTech companies worldwide, delivering clinical research and regulatory solutions that accelerate innovation, and drive success from concept to commercialization.

For more information, please visit www.avaniaclinical.com.

About Avania

Avania is the leading global MedTech advisory and clinical development partner with a focus on medical devices, diagnostics/IVDs, and digital health. Core offerings include full service clinical research outsourcing, market access, reimbursement, regulatory, and product development advisory services. Avania's vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.

Media Contact:
Jason Monteleone
Tel: +1 (978) 760-8043
Email: Jason.Monteleone@avaniaclinical.com


© 2025 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.